Alice Goodman

Two angiogenesis inhibitors that are widely used in metastatic renal cell carcinoma did not improve survival compared with placebo when used as adjuvant treatment, a new study found.

Researchers have come up with a potential blood-based biomarker that can identify men with castration-resistant prostate cancer who are not likely to respond to enzalutamide (XTANDI).

Preliminary studies suggest that inhibition of fibroblast growth factor receptors (FGFR) 1, 2, 3, and 4 may be a promising approach for the treatment of bladder cancers and other cancers that harbor FGFR alterations.

A comprehensive molecular characterization of muscle-invasive urothelial bladder carcinoma suggests multiple opportunities for therapeutic intervention.

The sequential use of two targeted treatments for metastatic renal cell carcinoma appears to yield similar total progression-free survival regardless of the order in which they are given, phase III study results indicate.

Patients with high-risk prostate cancer who undergo 18 months of androgen blockade live as long as those who have 36 months of treatment, according to results of a recent phase III study.

New York-Satraplatin, an oral platinum analog in late-stage development as second-line chemotherapy for hormone-refractory prostate cancer, has shown encouraging results in phase III trials, said Oliver Sartor, MD, associate professor of medicine at the Lank Center for Genitourinary Oncology at Dana Farber Cancer Institute, Boston. Dr. Sartor, who reviewed phase III results of the drug at the recent Chemotherapy Foundation Symposium here, said satraplatin is one of the most promising new agents under study for hormone-refractory disease.

New York-The administration of sipuleucel-T (Provenge), an investigational immunotherapy designed to stimulate a patient's immune response, followed by docetaxel chemotherapy prolonged survival in men with asymptomatic androgen-independent prostate cancer (AIPC), according to a recently released study. Median survival in these men was 14 months longer than would have been predicted by a prostate cancer survival nomogram, said Daniel Petrylak, MD, associate professor of medicine and director of genitourinary oncology at Columbia Presbyterian Medical Center in New York.

New York-Several promising agents in early stages of development may find a role in the treatment of prostate cancer, and two ongoing cooperative group trials will provide more definitive evidence about how best to use docetaxel (Taxotere) in the treatment of hormone-refractory prostate cancer (HRPC). At the Mount Sinai School of Medicine Chemotherapy Foundation Symposium here, the developments were reviewed by Noah M. Hahn, MD, assistant professor of medicine at the Indiana University Cancer Center in Indianapolis.